Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1081 details
Primary information
ID10453
Therapeutic IDTh1081
Protein NameAntithymocyte globulin
SequenceNA
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting point61 (FAB fr
Half-life2-3 days
DescriptionPolyclonal rabbit anti-thymocyte globulin. Used to suppresses certain types of immune cells ascribed to acute organ rejection in transplant patients by selective depletion of T-cells.
Indication/DiseaseFor prevention of renal transplant rejection
PharmacodynamicsAntithymocyte Globulin (ATG)is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts.
Mechanism of ActionBinds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis.
ToxicityNot known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk.
MetabolismMost likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.
AbsorptionT-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4–8 hours post-infusion after first and last IV doses, respectively, when given for 7–11 days.
NA
ClearanceNA
CategoriesImmunologic Factors and Immunosuppressive Agents
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionCanakinumab results in increased immunosuppressive effects; increases the risk of infection
TargetNA
Brand NameAntithymocyte globulin
CompanyPfizer
Brand DescriptionPfizer
Prescribed ForNA
Chemical NameNA
FormulationPowder for injection 25 mg vials
Physical Appearance NA
Route of AdministrationIntravenous infusion
Recommended DosageUsual Adult Dose for Renal Transplant: 1.5 mg/kg/day by IV infusion for 7 to 14 days. Anti-thymocyte globulin (rabbit) should be infused over a minimum of 6 hours for the first infusion and over at least 4 hours on subsequent days of therapy. Premedication with corticosteroids, acetaminophen, and/or an antihistamine 1 hour prior to the infusion is recommended and may reduce the incidence and intensity of side effects during the infusion.
ContraindicationAcute viral illness; hypersensitivity to leporine proteins; previous hypersensitivity to anti-thymocyte globulin.
Side EffectsNA
Useful Link 1NA
Useful Link 2NA
RemarksNA


Primary information
ID10454
Therapeutic IDTh1081
Protein NameAntithymocyte globulin
SequenceNA
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting point62 (FAB fr
Half-life2-3 days
DescriptionPolyclonal rabbit anti-thymocyte globulin. Used to suppresses certain types of immune cells ascribed to acute organ rejection in transplant patients by selective depletion of T-cells.
Indication/DiseaseFor prevention of renal transplant rejection
PharmacodynamicsAntithymocyte Globulin (ATG)is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation. ATG reduces the host immune response against tissue transplants or organ allografts.
Mechanism of ActionBinds to multiple, T-cell specific antigens leading to T-lymphocyte cell death via complement mediated cytotoxicity or apoptosis.
ToxicityNot known whether ATG (rabbit) distributes into human milk; however, other immunoglobulins are distributed into human milk.
MetabolismMost likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production.
AbsorptionT-cell depletion usually observed within 1 day after initiating therapy. Average 21.5 and 87 mcg/mL 4–8 hours post-infusion after first and last IV doses, respectively, when given for 7–11 days.
NA
ClearanceNA
CategoriesImmunologic Factors and Immunosuppressive Agents
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionRilonacept results in increased immunosuppressive effects; increases the risk of infection
TargetNA
Brand NameThymoglobulin
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1NA
Useful Link 2NA
RemarksNA